Catalog No.: PC-23971Not For Human Use, Lab Use Only.
Reparixin (Repertaxin) is a potent, selective, non-competitive allosteric inhibitor of CXCL8 receptor CXCR1 and CXCR2 activation with IC50 of 1 nM and 100 nM, respectively.
Reparixin (Repertaxin) is a potent, selective, non-competitive allosteric inhibitor of CXCL8 receptor CXCR1 and CXCR2 activation with IC50 of 1 nM and 100 nM, respectively. Reparixin inhibited the chemotaxis of neutrophils induced by human CXCL8 or rat CINC-1, but not that induced by fMLP, PAF or LTB(4), in a concentration-dependent manner. Reparixin also prevented CXCL8-induced calcium influx but not CXCL8 binding to purified rat neutrophils. Reparixin dose-dependently (3-30 mg kg(-1)) inhibited the increase in vascular permeability and neutrophil influx. Reparixin effectively suppressed the increase in tissue (intestine and lungs) and serum concentrations of TNF-alpha and the reperfusion-associated lethality.
